Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
The chart shows the growth of an initial investment of $10,000 in Alkermes Inc. plc, comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
Alkermes Inc. plc (ALKS) has returned 24.38% so far this year and 19.44% over the past 12 months. Looking at the last ten years, ALKS has achieved an annualized return of -0.23%, underperforming the Benchmark (SPY), which averaged 12.23% per year.
The table below presents the monthly returns of Alkermes Inc. plc (ALKS) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 20.99% | -10.26% | 20.72% | -2.71% | ||||||||
| 2025 | 8.35% | 10.35% | -3.79% | -12.82% | 6.54% | -6.53% | -7.18% | 9.65% | 3.06% | 2.10% | -2.50% | -4.51% |
| 2024 | -1.78% | 10.21% | -9.07% | -9.55% | -1.89% | 1.86% | 13.55% | 4.79% | 0.50% | -8.74% | 12.22% | -0.83% |
| 2023 | 9.61% | -6.41% | 5.19% | 1.75% | 1.12% | 7.82% | -6.24% | -4.44% | -13.55% | -0.21% | 14.68% | |
| 2022 | 9.96% | -3.68% | 6.26% | 9.07% | 3.68% | 0.20% | -14.24% | -7.18% | -5.54% | 0.18% | 8.73% | 4.98% |
| 2021 | 5.32% | -11.03% | -2.71% | 16.99% | 1.84% | 7.31% | 5.29% | 19.31% | -1.63% | -1.66% | -27.66% | 8.69% |
| 2020 | -15.03% | 19.09% | -31.00% | -3.38% | 20.56% | 18.76% | -7.40% | -9.12% | 0.42% | -2.17% | 10.94% | 8.42% |
| 2019 | 13.66% | 1.65% | 8.99% | -17.25% | -23.15% | 4.89% | 1.27% | -9.61% | -5.93% | -0.46% | 7.30% | -2.81% |
| 2018 | 3.96% | 0.55% | 1.61% | -5.30% | 6.50% | -13.05% | 5.41% | 2.66% | -4.80% | -3.75% | -2.85% | -19.04% |
| 2017 | -2.33% | 3.76% | 2.52% | -0.10% | -1.67% | 0.83% | -6.37% | -7.52% | 0.14% | -3.71% | 6.37% | 5.29% |
| 2016 | 16.43% | 16.64% | -5.24% | 15.19% | -12.32% | 6.93% | 6.98% | 12.96% | -1.84% |
The charts below present risk-adjusted performance metrics for Alkermes Inc. plc (ALKS) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of ALKS compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
The current Alkermes Inc. plc volatility is 4.14%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities And Equity (USD) | 2.49B | 2.06B | 2.14B | 1.96B | 2.02B | 1.95B | 1.81B | 1.83B | 1.80B | 1.73B | 1.86B | 1.92B | 1.47B | 1.44B | 452.45M |
| Equity Attributable To Parent (USD) | 1.82B | 1.46B | 1.20B | 1.04B | 1.11B | 1.07B | 1.09B | 1.17B | 1.20B | 1.21B | 1.31B | 1.40B | 952.37M | 853.85M | 392.02M |
| Equity Attributable To Noncontrolling Interest (USD) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Equity (USD) | 1.82B | 1.46B | 1.20B | 1.04B | 1.11B | 1.07B | 1.09B | 1.17B | 1.20B | 1.21B | 1.31B | 1.40B | 952.37M | 853.85M | 392.02M |
| Other Non-current Liabilities (USD) | - | - | - | - | - | - | - | - | - | 21.28M | - | 35.88M | 62.98M | 47.74M | - |
| Long-term Debt (USD) | - | - | - | - | - | - | - | - | - | 283.67M | 349.94M | 357.97M | 369.01M | 444.46M | - |
| Noncurrent Liabilities (USD) | 124.26M | 125.39M | 413.32M | 422.48M | 440.61M | 444.49M | 328.85M | 313.95M | 303.30M | 304.95M | 305.26M | 393.85M | 431.99M | 492.20M | 12.37M |
| Other Current Liabilities (USD) | 353.04M | 348.61M | 371.46M | 385.81M | 338.31M | 321.05M | 336.85M | 300.01M | 235.60M | 165.72M | 198.81M | 98.25M | 67.65M | 70.76M | - |
| Wages (USD) | 82.45M | 70.96M | 83.11M | 79.09M | 77.26M | 71.18M | - | - | - | - | - | - | - | - | - |
| Accounts Payable (USD) | 107.95M | 45.63M | 65.65M | 32.84M | 55.72M | 46.03M | 54.26M | 39.77M | 55.53M | 46.28M | 37.40M | 32.34M | 18.28M | 18.40M | - |
| Current Liabilities (USD) | 543.44M | 465.20M | 520.22M | 497.74M | 471.29M | 438.26M | 391.11M | 339.77M | 291.12M | 211.99M | 236.21M | 130.58M | 85.93M | 89.16M | 48.06M |
| Liabilities (USD) | 667.70M | 590.59M | 933.54M | 920.23M | 911.90M | 882.75M | 719.96M | 653.72M | 594.42M | 516.94M | 541.47M | 524.44M | 517.92M | 581.37M | 60.43M |
| Other Non-current Assets (USD) | 336.11M | 412.65M | 423.77M | 508.31M | 621.26M | 488.76M | 481.27M | 531.77M | 447.48M | 352.73M | 466.78M | 299.33M | 197.28M | 175.22M | 104.47M |
| Intangible Assets (USD) | - | - | - | - | - | - | - | - | 256.17M | 318.23M | 379.19M | 479.41M | 575.99M | 617.85M | - |
| Fixed Assets (USD) | 221.72M | 227.56M | 226.94M | 325.36M | 341.05M | 350.00M | 362.17M | 309.99M | 284.74M | 264.79M | 254.82M | 265.74M | 288.44M | 303.00M | 95.02M |
| Noncurrent Assets (USD) | 557.83M | 640.21M | 650.72M | 833.67M | 962.32M | 838.76M | 843.43M | 841.76M | 988.38M | 935.75M | 1.10B | 1.04B | 1.06B | 1.10B | 199.49M |
| Other Current Assets (USD) | 1.40B | 847.94M | 966.62M | 660.92M | 598.64M | 710.09M | 603.08M | 600.83M | 481.98M | 536.58M | 561.06M | 673.89M | 240.49M | 203.01M | 209.57M |
| Inventory (USD) | 196.63M | 182.89M | 186.41M | 181.42M | 150.34M | 125.74M | 101.80M | 90.20M | 93.28M | 63.00M | 38.41M | 51.36M | 43.48M | 39.76M | 20.43M |
| Accounts Receivable (USD) | 334.03M | 384.53M | 332.48M | 287.97M | 313.19M | 275.14M | 257.09M | 292.22M | 233.59M | 191.10M | 155.49M | 151.55M | 124.62M | 96.38M | 22.97M |
| Current Assets (USD) | 1.93B | 1.42B | 1.49B | 1.13B | 1.06B | 1.11B | 961.97M | 983.25M | 808.84M | 790.68M | 754.96M | 876.79M | 408.59M | 339.15M | 252.96M |
| Assets (USD) | 2.49B | 2.06B | 2.14B | 1.96B | 2.02B | 1.95B | 1.81B | 1.83B | 1.80B | 1.73B | 1.86B | 1.92B | 1.47B | 1.44B | 452.45M |
Commodore Capital completely exited its 3.2 million share position in Viridian Therapeutics (worth $69 million) on February 17, 2026, reducing the holding from 3.4% of the fund's assets to zero. This comes despite Viridian's stock being up 75% over the past year and entering a catalyst-heavy 2026 with FDA approval decisions and Phase 3 data expected. The exit suggests the fund may be taking profits after the strong rally or reallocating capital to other clinical-stage biotech names.
Commodore Capital increased its stake in Spyre Therapeutics by 400,161 shares ($10.46 million) in Q4, bringing its total position to $78.24 million (5.21% of AUM). SYRE stock has surged 63% over the past year, significantly outperforming the S&P 500's 13% gain. The preclinical biotech company, focused on inflammatory bowel disease treatments, has a strong balance sheet with $757 million in cash and expects runway into H2 2028, with six Phase 2 readouts expected in 2026.
The Irish High Court has sanctioned Avadel Pharmaceuticals' scheme of arrangement without modification, allowing Alkermes to acquire Avadel's entire issued share capital. The transaction is expected to close on February 12, 2026, with trading of Avadel shares on Nasdaq halting on February 11, 2026.
Avadel Pharmaceuticals shareholders have approved the proposed acquisition by Alkermes plc through a scheme of arrangement. The approval was overwhelming, with 97.41% of votes cast in favor at the scheme meeting and 96.53% approval at the extraordinary general meeting. The transaction is expected to proceed pending satisfaction of remaining conditions.
Avadel Pharmaceuticals announced the mailing of a proxy statement regarding its proposed acquisition by Alkermes, with scheme and extraordinary general meetings scheduled for January 12, 2026, to vote on the transaction.
Multiple corporate deals and strategic investments highlighted this week, including Kirin's potential Four Roses acquisition, quantum computing companies seeking U.S. government equity stakes, and Six Flags attracting activist investor interest with Travis Kelce's involvement.
Law firm Monteverde & Associates is investigating the proposed sale of Avadel Pharmaceuticals to Alkermes, where shareholders will receive $18.50 per share plus a potential additional $1.50 contingent on FDA approval of LUMRYZ™ by end of 2028.
Alkermes agreed to acquire Avadel Pharmaceuticals for up to $20 per share, valuing the deal at $2.1 billion. The acquisition includes the narcolepsy drug Lumryz and is expected to close in Q1 2026, with potential additional payment contingent on FDA approval.
Alkermes (NASDAQ:ALKS) was analyzed by 6 analysts in the last quarter, with a range of viewpoints from bullish to bearish. The analysts provided an average 12-month price target of $36.33, with a high of $48.00 and a low of $31.00. The article also provides financial insights into Alkermes, including its market capitalization, revenue growth, net margin, and debt management.
Orchestra BioMed Holdings, Inc. (OBIO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
